E-Mail IMAGE: The tests are ordered chronologically. Each row represents the biomarker test combination for one patient. Numbers shown on the right indicate the number of patients who received the same biomarker... view more Credit: van de Ven, Michiel, et al. Philadelphia, March 15, 2021 - Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in The Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients.